Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) Net Margin (2022 - 2025)

Historic Net Margin for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Q3 2025 value amounting to 7.47%.

  • Arcutis Biotherapeutics' Net Margin rose 1002800.0% to 7.47% in Q3 2025 from the same period last year, while for Sep 2025 it was 13.94%, marking a year-over-year increase of 1270300.0%. This contributed to the annual value of 71.25% for FY2024, which is 3685400.0% up from last year.
  • Latest data reveals that Arcutis Biotherapeutics reported Net Margin of 7.47% as of Q3 2025, which was up 1002800.0% from 19.49% recorded in Q2 2025.
  • Arcutis Biotherapeutics' Net Margin's 5-year high stood at 7.47% during Q3 2025, with a 5-year trough of 14856.41% in Q3 2022.
  • Its 4-year average for Net Margin is 1736.54%, with a median of 149.22% in 2023.
  • Its Net Margin has fluctuated over the past 5 years, first skyrocketed by 147072000bps in 2023, then skyrocketed by 333200bps in 2025.
  • Quarter analysis of 4 years shows Arcutis Biotherapeutics' Net Margin stood at 2432.25% in 2022, then soared by 80bps to 490.05% in 2023, then surged by 97bps to 15.12% in 2024, then skyrocketed by 149bps to 7.47% in 2025.
  • Its Net Margin stands at 7.47% for Q3 2025, versus 19.49% for Q2 2025 and 38.06% for Q1 2025.